Xospata Gilteritinib

Fact of Medicine

  • Brand Name: Xospata
  • Innovator Brand Name: Xospata
  • API: Gilteritinib
  • Packaging: 90 Tablets
  • Strength: 40mg
  • Manufacturer Name: Astellas Pharma US, Inc.
Get Price
Categories: ,


Uses of medication: Xospata (Gilteritinib) is a kinase inhibitor used for the treatment of adult patients with FLT3 mutated relapsed or refractory acute myeloid leukemia (AML).

Dosage: The recommended starting gilteritinib dose is 120 mg orally once daily either with or without food. Do not break or crush gilteritinib tablets. Administer the tablets orally about the same time each day. If a gilteritinib dose is missed or not taken at the usual time, administer the dose promptly on the same day, and at least 12 hours prior to the next scheduled dose. Never administer 2 doses within 12 hours.

Treatment Reactions: The most commonly reported gilteritinib side effects include:

  • Arthralgia
  • Fatigue
  • Fever
  • Mucositis
  • Edema
  • Rash
  • Dyspnea
  • Nausea
  • Cough
  • Constipation
  • Eye disorders
  • Headache
  • Dizziness
  • Hypotension
  • Vomiting
  • Renal impairment
  • Transaminase increased
  • Noninfectious diarrhea

Warning & Precautions

  • The xospata uses should be avoided in patients with hypersensitivity to gilteritinib or any of the excipients.
  • Patients should be assessed for blood counts and blood chemistries, prior to the initiation of xospata 40 mg.
  • Patients should be performed for the electrocardiogram (ECG) before initiation of gilteritinib treatment.
  • Women with childbearing age and taking treatment with gilteritinib 40 mg should avoid becoming pregnant.
  • Lactating women shouldn’t breastfeed during treatment with xospata 40 mg and for at least 2 months after the last dose.

More Info.

Storage: Store gilteritinib tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container until dispensed. Protect this medication from the light, humidity and moisture.

Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship XOSPATA at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the XOSPATA Tablets.

Buying Procedure: In order to buy XOSPATA, you can contact us at ourToll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with your Valid ID Proof, Prescription Letter and Medical Reports.

Conclusion: Use of gilteritinib at 120 mg once daily in patients with FLT3 mutated relapsed or refractory AML (Acute Myeloid Leukemia) led to the durable CR+CRh and the transfusion benefit, indicating a palliative benefit to the patients receiving this medication.

Commonly Asked Questions

What does Xospata contain as an active substance?

The medication Xospata specifically contains the active substance Gilteritinib.

From which class of drug Gilteritinib belongs?

Gilteritinib basically belongs to a class of drugs named tyrosine kinase inhibitors (TKIs).

How does Gilteritinib act?

As an oral drug, gilteritinib acts in order to stop leukemia cells from forming FLT3 protein. This can help stop or block the leukemia cells from growing rapidly.

How much does xospata cost?

The xospata price in India may vary depending on the wholesaler/pharmacy you visit. Cost for the xospata 40 mg is around 18,29,808 INR for a supply of 90 tablets.

Where can I get Gilteritinib at the best price?

In order to get the best gilteritinib price, always buy this medication from that Pharmaceutical Wholesaler Company which is WHO-GDP and ISO certified.

Can I get Gilteritinib (Xospata) even if I am not based in India?

The Indian Pharma helps patients in accessing or importing Gilteritinib (Xospata), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Send your inquiry to find Xospata (Gilteritinib Tablets) in UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia, Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand. China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.